AtriCure, Inc. $ATRC Stock Holdings Boosted by Vanguard Group Inc.

Vanguard Group Inc. grew its stake in shares of AtriCure, Inc. (NASDAQ:ATRC) by 1.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 4,903,755 shares of the medical device company’s stock after acquiring an additional 62,861 shares during the period. Vanguard Group Inc. owned about 0.10% of AtriCure worth $193,993,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. PNC Financial Services Group Inc. lifted its position in shares of AtriCure by 6.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 6,188 shares of the medical device company’s stock valued at $218,000 after acquiring an additional 380 shares during the last quarter. Scotia Capital Inc. lifted its position in shares of AtriCure by 1.2% during the 3rd quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock valued at $1,328,000 after acquiring an additional 457 shares during the last quarter. First Bank & Trust lifted its position in shares of AtriCure by 6.0% during the 4th quarter. First Bank & Trust now owns 8,805 shares of the medical device company’s stock valued at $348,000 after acquiring an additional 495 shares during the last quarter. Aster Capital Management DIFC Ltd lifted its position in shares of AtriCure by 197.1% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 811 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 538 shares during the last quarter. Finally, Captrust Financial Advisors lifted its position in shares of AtriCure by 8.9% during the 2nd quarter. Captrust Financial Advisors now owns 7,299 shares of the medical device company’s stock valued at $239,000 after acquiring an additional 598 shares during the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

Analysts Set New Price Targets

ATRC has been the subject of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $45.00 price objective on shares of AtriCure in a research report on Thursday, February 12th. Citigroup reiterated an “outperform” rating on shares of AtriCure in a research report on Wednesday, February 18th. JPMorgan Chase & Co. downgraded AtriCure from an “overweight” rating to a “neutral” rating and set a $36.00 price objective for the company. in a research report on Wednesday, February 11th. Freedom Capital upgraded AtriCure to a “strong-buy” rating in a research report on Wednesday, April 1st. Finally, UBS Group cut their price objective on AtriCure from $60.00 to $55.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $48.71.

Insider Activity

In other news, insider Vinayak Doraiswamy sold 5,000 shares of the stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $29.83, for a total value of $149,150.00. Following the completion of the sale, the insider owned 96,875 shares in the company, valued at $2,889,781.25. This represents a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.00% of the stock is owned by insiders.

AtriCure Price Performance

ATRC opened at $26.28 on Monday. The stock has a fifty day moving average of $29.24 and a 200-day moving average of $34.28. The firm has a market capitalization of $1.33 billion, a P/E ratio of -262.80 and a beta of 1.28. AtriCure, Inc. has a 12-month low of $26.08 and a 12-month high of $43.18. The company has a quick ratio of 3.18, a current ratio of 4.29 and a debt-to-equity ratio of 0.15.

AtriCure (NASDAQ:ATRC) last released its earnings results on Tuesday, May 5th. The medical device company reported $0.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.07. The company had revenue of $141.25 million during the quarter, compared to analyst estimates of $139.75 million. AtriCure had a positive return on equity of 0.29% and a negative net margin of 0.83%.The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.14) earnings per share. AtriCure has set its FY 2026 guidance at 0.000-0.040 EPS. Equities analysts forecast that AtriCure, Inc. will post 0.01 EPS for the current fiscal year.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.